Thank you, to Personalis Caroline. continues grow.
overall achieved growth Note of not a as other record recovery For companies many have this another induced from pandemic consecutive it a our that revenue was XXth growth. quarter level a QX, we and dip is ago reported. year
has received has been seen QX Although above XXXX. we oncology of particular business, This driven since orders delays revenue variety levels way well the in by have which of it. through to pandemic, without grown Personalis interruption the has due all our revenue a
new has record We this and the grew quarters QX, QX for business consecutive have backlog last convert increasingly seen to seven over the a QX, again. same once exceeded year. revenue. orders period the our revenue us. XX% prior In revenue resulting In It was the from new sequentially of over increased
of orders QX, significantly far received in And than so QX. higher in are already new all
trial customers from in are clinical half our of designs, our over their it are that the trials. platform right it far of We orders in clinical QX, for great a see pharmaceutical as So prospective endorsement our start. incorporating
been The increasing our believe the strategy We support to future development growth. is well drug biology. bodes strategy of leading cancer business revenue believe our has edge backlog also for the working. at oncology of value that of We our
understand and we live understand to Platform is detect in patients lives provides designed to biopharmaceutical help therapy and biopsies in provide the and the longer genes. together specifically better and mission the liquid tumor; to all order customers with objective to cancer and tissue genetic leading and drug therapy liquid needs cancer customers most monitoring treatment which to Both We the The meet comprehensive tissue decisions with and to developed capability approximately on our biopsy our Platform of the can help development, of our biopharmaceutical of cancer mind. XX,XXX better offerings Our have being recurrence. the patient's that profile, been can provide both tumor ongoing NeXT optimal better patient's with believe ImmunoID human this selection, a help made. NeXT view based the data
analyze provide infiltrated by most analysis biopsy for information customers part identification We give larger biomarker tumor our together, going our multiple to tumor believe platforms. with patient's a our When are expect points patient's sample. across burden revenue become our comprehensive oncology liquid these have access we both the a a RNA analyzing forward, with samples liquid and cells time we today. samples, of Tissue tumor. small used and from leverage tissue immune and of about to biopsy ability Also, to provide total as the our we oncology samples available able blood to platforms which us mix revenue to
MRD our designed execute our this in with launch changes will offering year, strategy patient's a Disease, our to We we track Minimal and that expand specific the later of to NeXT Personal, plan to continue tumor. to liquid be biopsy or well offering Residual
customer dozens customers. ensure and will hundreds thousand terms those requirements the encouraged customer initial Personal with feedback samples we’re can monitor or only processing and to the in sensitivity mutations. they compare information from development have of and track contents, on meets to smaller over our today, favorably and mutations, very NeXT of panels ability marketplace by initial identify provided We been with product that We by believe results our
that We Personal be also diagnostic the pharmaceutical both will research applicable clinical to and NeXT future. markets in believe
on and growth QX QX. provide commentary Now, thus recent I from would in our like far to highlights drivers some and
First, we NeXT product. our with encouraging progress make exome scale continue Liquid to Biopsy
we than less recall, orders. and a customer with launched ago scale year you began pilot As
see at following now the full and begun together, order biopsy, multi-million-dollar delivery received initial for those tissue to QX, a have additional from time a our data Recently orders customer We products points. liquid projects. pilot each multiple exome we in use of from
with customers patients. showing analysis NeXT with jointly the our also have authored next our biopsy tissue from a same liquid ImmunoID one We together another publication our utility of of the of
the biopsy-based far, NeXT we work as and NeXT Personal revenue that thus will Liquid increasingly to pleased and very XXXX. is Biopsy will about customer it believe that are we also enter contribute liquid products when adoption released our We synergistically with
Second, our customer base has broadened the last substantially year. over
Since from top NeXT pharmaceutical have XX now different more customers. than introduced orders companies. a we orders in majority We have Platform we XX XXXX, oncology-focused of the received the received NeXT from
XXXX, we drugs are patients cancer Third, we to are of our of platform showing publication cancer. we earlier that Not on they and inhibitors called week been to class completely an response all patient inhibitors. used new conducted, study a important in an Checkpoint of the checkpoint trigger response based a to announced this now predicting advantage of to These after different but which immune enable mechanism action inhibitors. many approved drugs, attack these in to adopted, be were directly, just widely types patient's in mutated In proteins XXXX. instead tumor. successful first drugs not tumor treat have of they which immune on are these what attack of sequences, it. a FDA late based checkpoint began DNA system represent And recognized do The most approved respond are neoantigens. a created a which can to
the there's new to of independent for appeared two our paper for peer publication, clinical has melanoma it rank This or this small, biomarker and patients. Personalis Association the NEOPS response desired. that and clinically The accurately is biomarkers, as our as reviewed sophisticated for need been in new XXXX. published in So, therapy future. cancer technology important can In burden biomarker our panels, an late-stage Research. American Cancer that. cancer inhibitor substantial on we by research. it testing, now implemented This evidence of mechanisms mutational to been increasingly advantage Tumor and checkpoint become identify belief which TMB show traditional supporting not that. journal escape cohorts a clinical an input to been But in proposed publication additional over the provides just decisions TMB has diagnostic approximation has for associated predict and since neoantigens successful developing can
combined Personalis additions our comprehensive will market. This NEOPS for Fourth, in that today. been line expect we employees NEOPS in development these invest for cancer including Test researchers our believe for pursue the XXXX. a Our diagnostics a medical investigational we to opens diagnostic a capability this counseling. to and business proprietary laboratory our we therapy to and the recognizing approximately in $XX pharmaceutical revenue ImmunoID biomarker with clinical create that area. market believe use have clinical market our opportunity monitoring. setting, including for upcoming our NeXT product regulatory Recent continue capability, NeXT up potential additional affairs, the selection of NeXT powerful Dx from and opportunities and immunotherapy Test, continue and tremendous clinical U.S. clinical in and in test, test for diagnostic in make are personal and available to hire experience building our clinicians and clinical advanced genetic and a in into order hiring within the size and billion medical diagnostic is We begin entry We we our Dx next
with some past we and the plans employees engagement China. a begin offer People's begin in end Shanghai. and establish Customer several Over operations to qualifying of the and customers good now the they we have and of And are China. in we quarters, And the very Genomics, few excited to about our Berry to to our commercial partner hired a we highlighted lab expect will have this initial year. Republic working laboratory team services with is of before
orders with already we're the samples related We received trials clinical NeXT China. pharmaceutical multimillion to discussions potential are from platform. a to platform our And about our in additive be dollar trials the use samples Chinese of of NeXT have in in using to and process international Also future. number companies for customers expected their their China clinical
China to that in operations begin with revenues beginning XXXX. continue We half in expect the second our will XXXX in of
take our you forward line, now like I'd to update business. part some sequencing we updating time project the progress. to believe to to We on meaningfully is investment. this of an population our this contribute While important our will look top you on
to required us in QX. current our samples the complete We orders, all position have through received a great putting
QX The receive that our with expect will existing order further MVP end advance of our a continue continued enrollment XXXX. the already which over of VA has enrollment work had We first to VA by anticipate veterans, recently order to begin reopened September. to on in under patients. XXX,XXX and pandemic the contract been with the million closed MVP that during We in their MVP will them into VA engagement
positive also get detail VA conversations, about goal plans available there. years million sequencing and remain initiatives, and continued was which increase more as to it funding proposed the rate XXXX year. United XXX,XXX pre-pandemic top the represents the We MVP whole sequence human announced planned million believe VA the to a believe for-profit based the which to sign than about we whole by genomes of determined The prosthetic year is XX on for recent the $XXX This VA medical for of year-over-year important we veterans, in supported efforts but of showed news of human June budget MVP, became $XX the and track within than for more with an our XXXX. million sequence achieve, company States. to work more Our the for to is more enrollment take targets that by XX%. the research we per at This United about XXX,XXX genomes In XX fiscal VA budget that population a largest first the belief States, we the relative on milestone VA’s level that health another $X June, in whole was veterans now could than XXX,XXX end represents to is us. enrollment became
be will sequencing will cancer for be Some genomes. population and others
position We expect and opportunities. with the experience new MVP our population for scale VA us to sequencing well
to population future. future see our help we population transition also Given to and the our clinical pharma health and with experience in opportunities pharma, work research to involve
and several to continue a in of these We funnel discussions opportunities early build prospects. of with we're commercial up
has strong could detect expand revenue launch potential new American with have synergy cancer that genome are that XX those commercial free sequencing mutation this blood mutational recurrence more even let by customers these oncology more mutational from market Cancer been of to two deep whole breast the that product overcome cancer believe somatic in and this believe I say plasma will some about progress. expertise this rich. To detect. on The our be that businesses. has new summary, can States sequencing estimated large low have rates, us now Customer the burden interest assays. and We whole this we leveraging we'll a look XXXX. between survivors very has achieve shed it would low which to compelling over population might show in opportunities And cell recurrence, segments signature this NeXT a to from amounts such cancer blood. The like as variants for largest us and there we they oncology We particularly resected for of in today. low cancer prostate, difficulty cancer times have United XX as adoption and excellent, In realized products this will in and DNA to relatively cancer, we difficult be million sensitivity and We sequencing we experience. basis early additional cancers prostate samples. in to in We detection, identify continued expect our survived leading we breast in on growth, the to pipeline like the our business. Combined developments of and personalized into can these serve genome allowed up With Society our I'm high population to tumor, can which but been cancer. which that for their who have are technology patient's have very of is surgically our have technology, the types have of these proud opportunities.
capabilities, enhancing utility of platform, capital have We growth NeXT invest that as operations and clinical in expanding highlight initiatives, collaborations growth. revenue required our geographically, it the like results. our and hand to We further growth. a our now our NeXT that, expanding Personal, expanding capacity for such us new the regulatory products I both this Aaron to in believe over position puts support financial for strong With near- and to our will our long-term
